Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | D2C7-IT |
| Trade Name | |
| Synonyms | D2C7-(scdsFv)-PE38KDEL |
| Drug Descriptions |
D2C7-IT is an immunotoxin engineered by linking a fragment of the D2C7 monoclonal antibody recognizing wild-type EGFR and EGFRvIII with Pseudomonas Exotoxin A (PE38KDEL), which targets tumor cells expressing wild-type EGFR and/or EGFRvIII, potentially resulting in decreased tumor growth (PMID: 28286803, PMID: 31142380). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C119739 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| 2141 V-11 + D2C7-IT | 2141 V-11 D2C7-IT | 0 | 3 |
| Atezolizumab + D2C7-IT | Atezolizumab D2C7-IT | 0 | 1 |
| D2C7-IT | D2C7-IT | 0 | 1 |